# US 2025/0082587 A1 · Method Of Treating Major Depressive Disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082587 A1
- Document ID: US20250082587A1
- Status: Published application
- Kind: A1
- Application number: 18/882,915
- Filed: 2024-09-12
- Published: 2025-03-13
- Earliest claimed: 2023-09-12
- Assignees: Clexio Biosciences Ltd.
- Applicants: Clexio Biosciences Ltd.
- Inventors: David DANGOOR
- Web page: https://patentgrep.com/patent/US20250082587A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods for safe and efficacious administration of esketamine and pharmaceutically acceptable salts thereof.

## Claims

### Claim 1

A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
a) determining or having determined said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score, and
b) orally administering an immediate release oral dosage form comprising 60 mg of esketamine or a pharmaceutically acceptable salt thereof, once daily for at least 28 days to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administration of the oral dosage form is at night.

### Claim 3 (depends on 2)

The method of claim 2, wherein the administration of the oral dosage form is before the subject goes to sleep.

### Claim 4 (depends on 1)

The method of claim 1, wherein the oral dosage form is self-administered by the patient.

### Claim 5 (depends on 1)

The method of claim 1, wherein following the administration of the oral dosage form, the patient is restricted from driving for no more than eight hours.

### Claim 6 (depends on 1)

The method of claim 1, further comprising the administration of a second medication other than (R)-ketamine.

### Claim 7 (depends on 6)

The method of claim 6, wherein the second medication comprises an antidepressant, an antimanic agent or an anxiolytic drug.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antidepressant is selected from the group consisting of mono-amine oxidase inhibitors, tricyclic antidepressants, serotonin specific reuptake inhibitors, serotonin noradrenergic reuptake inhibitors and noradrenaline reuptake inhibitors.

### Claim 9 (depends on 1)

The method of claim 1, wherein the treatment of major depressive disorder (MDD) comprises an improvement from baseline in the subject's measured Montgomery-Åsberg Depression Rating Scale (MADRS) score after at least 28 days when compared to placebo.

### Claim 10 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has not responded to adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 11 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has failed to demonstrate an improvement of up to 25% in the MADRS score after adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 12 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has failed to demonstrate an improvement of up to 50% in the MADRS score after adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 13 (depends on 1)

The method of claim 1, wherein prior to the administration, the human patient has demonstrated an improvement of between 25 and 50% in the MADRS score after adequate doses and treatment durations of antidepressants other than ketamine or esketamine.

### Claim 14 (depends on 1)

The method of claim 1, wherein the major depressive disorder (MDD) is moderate-to-severe major depressive disorder (MDD).

### Claim 15 (depends on 1)

The method of claim 1, wherein the major depressive disorder (MDD) is moderate major depressive disorder (MDD).

### Claim 16 (depends on 1)

The method of claim 1, wherein the major depressive disorder (MDD) is severe major depressive disorder (MDD).

### Claim 17 (depends on 1)

The method of claim 1, wherein the esketamine is esketamine hydrochloride.

### Claim 18

A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
a) determining or having determined whether said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score is at least 28, and
b) orally administering an immediate release oral dosage form comprising 60 mg of immediate release esketamine or a pharmaceutically acceptable salt thereof, once daily for at least 28 days to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28.

### Claim 19

A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
a) determining or having determined that said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score is at least 28, and
b) orally administering an immediate release oral dosage form comprising 60 mg of immediate release esketamine or a pharmaceutically acceptable salt thereof, once daily for at least 28 days to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28.

### Claim 20

A method of treating major depressive disorder (MDD) in a subject in need thereof comprising:
a) determining or having determined said subject's Montgomery-Åsberg Depression Rating Scale (MADRS) score, and
b) orally administering an immediate release oral dosage form comprising 60 mg of esketamine or a pharmaceutically acceptable salt thereof, to the subject that is determined to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 28; and
wherein the administration is once daily for at least 28 days.
